|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Oncolytics Biotech Inc.
| | | Phone: | (403) 670-7377 | Fax: | (403) 283-0858 | Year Established: | 1998 | Employees: | 11 | Ticker: | ONCYF | Exchange: | OTCQX | Main Contact: | Matt Coffey, Ph.D., President & CEO | | Other Contacts: | Kirk Look, CFO Andrew de Guttadauro, Global Head of Business Development
| | Company Description | Oncolytics is a biotechnology company developing REOLYSIN, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to potentially treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. | |
|
|
|
|
|